On March 12, 2025, Glenmark Pharmaceuticals Ltd. unveiled its latest addition to the cardiometabolic portfolio with the launch of Empagliflozin and its fixed-dose combinations (FDCs) in India. The drug, marketed under the name Glempa, will be available in doses of 10 mg and 25 mg of Empagliflozin. Additionally, Glenmark introduced two FDCs—Glempa-L (Empagliflozin + Linagliptin) and Glempa-M (Empagliflozin + Metformin). These medications are aimed at adults with Type 2 Diabetes Mellitus (T2DM) and those suffering from heart failure (HF) and cardiovascular diseases (CVD).

Empagliflozin’s Role in Cardiometabolic Care

Empagliflozin, a well-known SGLT2 inhibitor, has already established itself as an effective treatment for Type 2 Diabetes (T2DM) and heart failure globally. The drug is designed to improve glycemic control, support weight loss, and reduce cardiovascular and renal risks in T2DM patients. Furthermore, studies have shown that Empagliflozin offers substantial cardiovascular benefits, particularly in patients with established cardiovascular disease (CVD). The EMPA-REG trial, a landmark clinical study, revealed that Empagliflozin resulted in a 14% reduction in major cardiovascular events, solidifying its position as an essential tool in cardiometabolic care.

Clinical Benefits and Effectiveness of Empagliflozin

The launch of Glempa and its FDCs comes with a wealth of clinical evidence supporting Empagliflozin’s effectiveness. In a 24-week study, a combination of Empagliflozin (12.5 mg) and Metformin (500/1000 mg) helped patients reduce their HbA1c by 1.9% to 2.1%, lose 3 to 3.8 kg, and decrease fasting blood sugar by 43.2 to 50.4 mg/dL. These results highlight Empagliflozin’s potency in managing blood sugar levels, especially in individuals with T2DM. Another clinical trial showed that Glempa-L, a combination of Empagliflozin and Linagliptin (5 mg), helped reduce HbA1c by 1.24%, promote weight loss of 2 to 2.7 kg, and improve fasting blood sugar levels significantly.

Glenmark’s Commitment to Cardiometabolic Care

Glenmark has long been a leader in cardiometabolic treatments, having launched numerous medications to address the growing prevalence of T2DM and cardiovascular diseases. With the launch of Empagliflozin and its FDCs, Glenmark reinforces its commitment to providing affordable, innovative treatments for Cardiometabolic care in India. The Glempa range will empower healthcare professionals to offer personalized treatment options, addressing the specific needs of their T2DM patients. The inclusion of Empagliflozin further strengthens Glenmark’s leadership in cardiometabolic care.

The Importance of Affordable Healthcare Solutions

The prevalence of cardiovascular diseases and diabetes is rapidly rising in India. According to the ICMR-INDIAB study, the overall prevalence of diabetes in India stands at 11.4%, with the number of heart failure cases attributed to coronary heart disease, hypertension, and obesity expected to rise significantly in the coming years. In light of this, Glenmark’s Glempa range offers a cost-effective solution that will help improve health outcomes for millions of patients across the country.

Strengthening Glenmark’s Global Presence

With its launch of Glempa, Glenmark continues to expand its global footprint. The company operates in over 80 countries, with manufacturing facilities across four continents. In 2023, Glenmark was ranked among the top 100 biopharmaceutical companies and continues to make strides in both the generics and biopharmaceutical sectors. The company's focus on sustainable practices was also recognized in 2023 when its Greenhouse Gas emissions reduction targets were approved by the Science Based Target Initiative (SBTi).

Conclusion

The launch of Empagliflozin and its fixed-dose combinations (FDCs) by Glenmark Pharmaceuticals marks a significant milestone in the treatment of T2DM and heart failure in India. These treatments are expected to provide patients with better glycemic control, weight loss, and reduced cardiovascular risks, addressing a critical need in cardiometabolic care. Glenmark's ongoing commitment to innovation and affordability will continue to shape the future of healthcare in India and globally.

The Upcoming IPOs in this week and coming weeks are Paradeep Parivahan, Divine Hira Jewellers.

The Current active IPO are Super Iron Foundry, PDP Shipping & Projects.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.